Haixi New Pharma

Haixi New Pharma is a China-based pharmaceutical company specializing in the development of high-end generic drugs and innovative small molecule therapeutics. Founded in 2012 and headquartered in Fuzhou, the company leverages its advanced formulation platforms to focus on therapeutic areas such as gastroenterology, cardiovascular health, and the central nervous system. Haixi New Pharma is notably recognized for its development of Tegoprazan, a potassium-competitive acid blocker (P-CAB) that was successfully commercialized in partnership with Luoxin Pharmaceuticals. The company maintains a robust pipeline of improved new drugs and high-barrier generics, utilizing its expertise in complex drug delivery systems. With a focus on the Chinese market, Haixi New Pharma operates integrated R&D and manufacturing facilities to support its goal of providing affordable, high-quality medicines. The firm has attracted significant investment from prominent Chinese venture capital firms to accelerate its clinical programs and industrialization efforts.